Free Trial

Gilead Sciences (GILD) Financials

Gilead Sciences logo
$135.00 -1.30 (-0.96%)
As of 09:47 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Annual Income Statements for Gilead Sciences

Annual Income Statements for Gilead Sciences

This table shows Gilead Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
18,108 13,501 4,628 5,455 5,386 123 6,225 4,592 5,665 480 8,510
Consolidated Net Income / (Loss)
18,106 13,488 4,644 5,460 5,364 89 6,201 4,566 5,613 480 8,510
Net Income / (Loss) Continuing Operations
18,106 13,488 4,644 5,460 5,364 89 6,201 4,566 5,612 479 8,510
Total Pre-Tax Income
21,659 17,097 13,529 7,799 5,160 1,669 8,278 5,814 6,859 690 9,796
Total Operating Income
22,193 17,633 14,124 8,200 4,287 4,071 9,918 7,330 7,605 1,662 10,022
Total Gross Profit
28,633 26,129 21,736 17,274 17,774 20,117 20,704 21,624 20,618 22,503 23,209
Total Revenue
32,639 30,390 26,107 22,127 22,449 24,689 27,305 27,281 27,116 28,754 29,443
Operating Revenue
32,151 30,390 26,107 22,127 22,449 24,689 27,305 27,281 27,116 28,754 29,443
Total Cost of Revenue
4,006 4,261 4,371 4,853 4,675 4,572 6,601 5,657 6,498 6,251 6,234
Operating Cost of Revenue
4,006 4,261 4,371 4,853 4,675 4,572 6,601 5,657 6,498 6,251 6,234
Total Operating Expenses
6,440 8,496 7,612 9,074 13,487 16,046 10,786 14,294 13,013 20,841 13,187
Selling, General & Admin Expense
3,426 3,398 3,878 4,056 4,381 5,151 5,246 5,673 6,090 6,091 5,774
Research & Development Expense
3,014 5,098 3,734 5,018 9,106 10,895 5,540 5,921 6,873 10,570 6,823
Impairment Charge
- - - - - 0.00 0.00 2,700 50 4,180 590
Total Other Income / (Expense), net
-534 -536 -595 -401 873 -2,402 -1,640 -1,516 -746 -971 -226
Interest Expense
688 964 1,118 1,077 995 984 1,001 935 944 977 1,024
Other Income / (Expense), net
154 428 523 676 1,868 -1,418 -639 -581 198 6.00 798
Income Tax Expense
3,553 3,609 8,885 2,339 -204 1,580 2,077 1,248 1,247 211 1,286
Net Income / (Loss) Attributable to Noncontrolling Interest
-2.00 -13 16 5.00 -22 -34 -24 -26 -52 0.00 0.00
Basic Earnings per Share
$12.37 $10.08 $3.54 $4.20 $4.24 $0.10 $4.96 $3.66 $4.54 $0.38 $6.84
Weighted Average Basic Shares Outstanding
1.46B 1.34B 1.31B 1.30B 1.27B 1.26B 1.26B 1.26B 1.25B 1.25B 1.24B
Diluted Earnings per Share
$11.91 $9.94 $3.51 $4.17 $4.22 $0.10 $4.93 $3.64 $4.50 $0.38 $6.78
Weighted Average Diluted Shares Outstanding
1.52B 1.36B 1.32B 1.31B 1.28B 1.26B 1.26B 1.26B 1.26B 1.26B 1.26B
Weighted Average Basic & Diluted Shares Outstanding
1.46B 1.34B 1.31B 1.30B 1.26B 1.26B 1.25B 1.25B 1.25B 1.25B 1.24B
Cash Dividends to Common per Share
$1.29 $1.84 $2.08 $2.28 $2.52 $2.72 $2.84 $2.92 $3.00 $3.08 $3.16

Quarterly Income Statements for Gilead Sciences

This table shows Gilead Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
1,045 2,180 1,430 -4,170 1,614 1,253 1,783 1,315 1,960 3,052 2,183
Consolidated Net Income / (Loss)
1,039 2,172 1,417 -4,170 1,614 1,253 1,783 1,315 1,960 3,052 2,183
Net Income / (Loss) Continuing Operations
1,039 2,172 1,417 -4,171 1,615 1,253 1,782 1,315 1,961 3,052 2,182
Total Pre-Tax Income
1,588 2,318 1,653 -4,486 2,053 956 2,167 1,649 2,429 3,641 2,077
Total Operating Income
1,665 2,623 1,612 -4,322 2,644 888 2,452 2,237 2,474 3,327 1,984
Total Gross Profit
5,157 5,486 5,024 5,134 5,410 5,971 5,988 5,127 5,581 6,200 6,301
Total Revenue
6,599 7,051 7,114 6,686 6,954 7,545 7,569 6,667 7,082 7,769 7,925
Operating Revenue
6,599 7,051 7,114 6,686 6,954 7,545 7,569 6,667 7,082 7,769 7,925
Total Cost of Revenue
1,442 1,565 2,090 1,552 1,544 1,574 1,581 1,540 1,501 1,569 1,624
Operating Cost of Revenue
1,442 1,565 2,090 1,552 1,544 1,574 1,581 1,540 1,501 1,569 1,624
Total Operating Expenses
3,492 2,863 3,411 9,456 2,766 5,083 3,536 2,890 3,107 2,873 4,317
Selling, General & Admin Expense
1,849 1,315 1,607 1,375 1,377 1,433 1,906 1,258 1,365 1,357 1,794
Research & Development Expense
1,643 1,548 1,754 5,651 1,389 1,900 1,630 1,632 1,552 1,516 2,123
Impairment Charge
0.00 0.00 50 2,430 0.00 1,750 - 0.00 190 0.00 400
Total Other Income / (Expense), net
-78 -304 40 -163 -592 68 -284 -588 -46 313 95
Interest Expense
230 232 252 254 237 238 248 260 254 256 254
Other Income / (Expense), net
152 -72 292 91 -355 306 -36 -328 208 569 349
Income Tax Expense
549 146 236 -315 438 -297 385 334 468 589 -105
Basic Earnings per Share
$0.84 $1.75 $1.14 ($3.34) $1.29 $1.00 $1.43 $1.06 $1.57 $2.46 $1.75
Weighted Average Basic Shares Outstanding
1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.24B 1.24B
Diluted Earnings per Share
$0.83 $1.73 $1.14 ($3.34) $1.29 $1.00 $1.43 $1.04 $1.56 $2.43 $1.75
Weighted Average Diluted Shares Outstanding
1.26B 1.26B 1.26B 1.25B 1.25B 1.25B 1.26B 1.26B 1.26B 1.25B 1.26B
Weighted Average Basic & Diluted Shares Outstanding
1.25B 1.25B 1.25B 1.25B 1.24B 1.25B 1.25B 1.24B 1.24B 1.24B 1.24B

Annual Cash Flow Statements for Gilead Sciences

This table details how cash moves in and out of Gilead Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
2,824 -4,622 -778 10,437 -6,309 -5,634 -659 74 673 3,906 -2,428
Net Cash From Operating Activities
21,250 17,047 11,898 8,400 9,144 8,168 11,384 9,072 8,006 10,828 10,019
Net Cash From Continuing Operating Activities
21,250 17,047 11,898 8,400 9,144 8,168 11,384 9,072 8,005 10,828 10,019
Net Income / (Loss) Continuing Operations
18,106 13,488 4,644 5,460 5,364 89 6,201 4,566 5,613 480 8,510
Consolidated Net Income / (Loss)
18,106 13,488 4,644 5,460 5,364 89 6,201 4,566 5,613 480 8,510
Depreciation Expense
161 177 233 226 255 288 329 323 354 381 370
Amortization Expense
937 981 1,053 1,203 1,149 1,192 1,721 1,780 2,339 2,386 2,390
Non-Cash Adjustments To Reconcile Net Income
944 974 942 2,161 5,272 8,451 2,760 5,718 2,002 10,305 2,537
Changes in Operating Assets and Liabilities, net
1,102 1,427 5,026 -650 -2,896 -1,852 373 -3,315 -2,303 -2,724 -3,788
Net Cash From Investing Activities
-12,475 -11,985 -16,069 14,355 -7,817 -14,615 -3,131 -2,466 -2,265 -3,449 -4,793
Net Cash From Continuing Investing Activities
-12,475 -11,985 -16,069 14,355 -7,817 -14,615 -3,131 -2,466 -2,266 -3,449 -4,794
Purchase of Property, Plant & Equipment
-747 -748 -590 -924 -825 -650 -579 -728 -585 -523 -563
Acquisitions
0.00 0.00 -10,426 0.00 -4,251 -25,920 -1,584 -1,797 -1,152 -4,840 -1,070
Purchase of Investments
-17,239 -25,976 -23,314 -10,389 -32,228 -20,770 -3,897 -1,942 -2,372 -736 -4,072
Sale and/or Maturity of Investments
5,511 14,739 18,261 25,858 29,921 32,718 2,910 2,002 1,844 2,592 909
Other Investing Activities, net
- - 0.00 -190 -434 7.00 19 -1.00 -1.00 58 2.00
Net Cash From Financing Activities
-5,884 -9,725 3,393 -12,318 -7,634 770 -8,877 -6,469 -5,125 -3,433 -7,745
Net Cash From Continuing Financing Activities
-5,884 -9,725 3,393 -12,318 -7,634 770 -8,877 -6,469 -5,126 -3,433 -7,745
Repayment of Debt
-5,013 -2,257 -2,141 -6,736 -2,872 -2,638 -4,895 -1,673 -2,529 -2,251 -2,228
Repurchase of Common Equity
-10,002 -11,001 -954 -2,900 -1,749 -1,583 -546 -1,396 -1,000 -1,150 -1,922
Payment of Dividends
-1,874 -2,455 -2,731 -2,971 -3,222 -3,449 -3,605 -3,709 -3,809 -3,918 -4,003
Issuance of Debt
9,902 5,293 8,985 0.00 - 8,184 0.00 0.00 1,980 3,464 0.00
Issuance of Common Equity
319 208 234 289 209 256 169 309 232 422 408
Effect of Exchange Rate Changes
-67 41 - - -2.00 43 -35 -63 57 -40 92

Quarterly Cash Flow Statements for Gilead Sciences

This table details how cash moves in and out of Gilead Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents
768 1.00 380 -1,367 -1,946 2,264 4,955 -2,065 -2,783 2,187 233
Net Cash From Operating Activities
2,338 1,755 2,169 2,219 1,325 4,309 2,975 1,757 827 4,108 3,327
Net Cash From Continuing Operating Activities
2,337 1,756 2,167 2,219 1,324 4,309 2,976 1,758 827 4,107 3,327
Net Income / (Loss) Continuing Operations
1,039 2,172 1,417 -4,170 1,614 1,253 1,783 1,315 1,960 3,052 2,183
Consolidated Net Income / (Loss)
1,039 2,172 1,417 -4,170 1,614 1,253 1,783 1,315 1,960 3,052 2,183
Depreciation Expense
83 86 91 94 98 94 95 97 93 90 90
Amortization Expense
598 598 597 596 596 596 598 599 598 596 597
Non-Cash Adjustments To Reconcile Net Income
507 517 975 6,158 728 2,300 396 979 368 7.00 1,183
Changes in Operating Assets and Liabilities, net
110 -1,617 -913 -459 -1,712 66 104 -1,232 -2,192 362 -726
Net Cash From Investing Activities
-483 -229 -727 -2,207 -307 -710 -225 -415 -2,116 -427 -1,835
Net Cash From Continuing Investing Activities
-483 -229 -728 -2,205 -309 -709 -226 -416 -2,116 -426 -1,836
Purchase of Property, Plant & Equipment
-139 -122 -215 -105 -130 -141 -147 -104 -107 -147 -205
Acquisitions
-243 -79 -279 -4,043 -152 -570 -75 -273 -21 -167 -609
Purchase of Investments
-645 -395 -680 -654 -34 -9.00 -39 -16 -2,308 -352 -1,396
Sale and/or Maturity of Investments
545 361 447 2,592 - - - 0.00 310 236 363
Other Investing Activities, net
-1.00 6.00 -1.00 5.00 7.00 11 35 -23 10 4.00 11
Net Cash From Financing Activities
-1,101 -1,519 -1,099 -1,361 -2,953 -1,379 2,260 -3,426 -1,567 -1,489 -1,263
Net Cash From Continuing Financing Activities
-1,100 -1,519 -1,100 -1,360 -2,954 -1,379 2,260 -3,426 -1,567 -1,489 -1,263
Repayment of Debt
-32 -2,328 -34 -116 -1,887 -194 -54 -1,938 -73 -146 -71
Repurchase of Common Equity
-150 -300 -150 -400 -100 -300 -350 -730 -527 -435 -230
Payment of Dividends
-944 -953 -943 -990 -972 -983 -973 -1,010 -994 -1,005 -994
Issuance of Common Equity
26 83 26 146 5.00 98 173 252 27 97 32
Effect of Exchange Rate Changes
13 -6.00 37 -18 -11 44 -55 19 73 -5.00 5.00

Annual Balance Sheets for Gilead Sciences

This table presents Gilead Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
51,716 56,977 70,283 63,675 61,627 68,407 67,952 63,171 62,125 58,995 59,023
Total Current Assets
24,762 19,588 31,823 35,836 30,296 15,996 14,772 14,443 16,085 19,173 18,342
Cash & Equivalents
12,851 8,229 7,588 17,940 11,631 5,997 5,338 5,412 6,085 9,991 7,564
Short-Term Investments
1,756 3,666 17,922 12,149 12,721 1,411 1,182 973 1,179 0.00 68
Accounts Receivable
5,854 4,514 3,851 3,327 3,582 4,892 4,493 4,777 4,660 4,420 4,913
Inventories, net
1,955 1,587 801 814 922 1,683 1,618 1,507 1,787 1,710 1,774
Prepaid Expenses
1,518 1,592 1,661 1,606 1,440 2,013 2,141 1,774 2,374 3,052 4,024
Plant, Property, & Equipment, net
2,276 2,865 3,295 4,006 4,502 4,967 5,121 5,475 5,317 5,414 5,606
Total Noncurrent Assets
24,678 34,524 35,165 23,833 26,829 47,444 48,059 43,253 40,723 34,409 35,075
Long-Term Investments
11,601 20,485 11,184 1,423 1,488 502 1,309 1,245 1,163 0.00 2,974
Goodwill
1,172 1,172 4,159 4,117 4,117 8,108 8,332 8,314 8,314 8,314 8,314
Intangible Assets
10,247 8,971 17,100 15,738 13,786 33,126 33,455 28,894 26,454 19,948 16,978
Noncurrent Deferred & Refundable Income Taxes
324 - - - - - - - - 2,378 1,964
Other Noncurrent Operating Assets
1,334 3,896 2,722 2,555 7,438 5,708 4,963 4,800 4,792 3,769 4,845
Total Liabilities & Shareholders' Equity
51,716 56,977 70,283 63,675 61,627 68,407 67,952 63,171 62,125 58,995 59,023
Total Liabilities
32,601 37,614 49,782 42,141 38,977 50,186 46,888 41,962 39,376 39,749 36,405
Total Current Liabilities
9,890 9,218 11,635 10,605 9,759 11,397 11,610 11,237 11,280 12,004 11,813
Short-Term Debt
982 0.00 2,747 2,748 2,499 2,757 1,516 2,273 1,798 1,815 2,807
Accounts Payable
1,178 1,206 814 790 713 5,180 705 905 550 833 715
Accrued Expenses
7,290 8,012 8,074 7,067 6,547 3,460 3,244 3,479 3,802 3,892 4,337
Other Current Liabilities
- - - - - - 6,145 4,580 5,130 5,464 3,953
Total Noncurrent Liabilities
22,711 28,396 38,147 31,536 29,218 38,789 35,278 30,725 28,096 27,745 24,592
Long-Term Debt
21,073 26,346 30,795 24,574 22,094 28,645 25,179 22,957 23,189 24,896 22,129
Noncurrent Deferred Revenue
1,243 1,753 6,794 5,922 6,115 5,016 4,767 3,916 2,039 830 896
Noncurrent Deferred & Payable Income Tax Liabilities
- - - - - 3,914 4,356 2,673 1,588 724 402
Other Noncurrent Operating Liabilities
395 297 558 1,040 1,009 1,214 976 1,179 1,280 1,295 1,165
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
19,113 19,363 20,501 21,534 22,650 18,221 21,064 21,209 22,749 19,246 22,618
Total Preferred & Common Equity
18,534 18,887 20,442 21,387 22,525 18,202 21,069 21,240 22,833 19,330 22,703
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
18,534 18,887 20,442 21,387 22,525 18,202 21,069 21,240 22,833 19,330 22,702
Common Stock
445 455 1,265 2,283 3,052 3,881 4,662 5,551 6,501 7,701 8,933
Retained Earnings
18,001 18,154 19,012 19,024 19,388 14,381 16,324 15,687 16,304 11,497 13,730
Accumulated Other Comprehensive Income / (Loss)
88 278 165 80 85 -60 83 2.00 28 132 39
Noncontrolling Interest
579 476 59 147 125 19 -5.00 -31 -84 -84 -84

Quarterly Balance Sheets for Gilead Sciences

This table presents Gilead Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets
61,876 62,337 62,373 62,125 56,292 53,579 54,525 58,995 56,434 55,721 58,533
Total Current Assets
13,456 14,287 15,980 16,085 14,041 12,317 14,779 19,173 16,901 14,718 17,874
Cash & Equivalents
4,936 5,704 5,705 6,085 4,718 2,772 5,037 9,991 7,926 5,144 7,330
Short-Term Investments
936 963 1,159 1,179 0.00 0.00 0.00 0.00 - 69 19
Accounts Receivable
4,162 4,229 4,790 4,660 4,669 4,663 4,587 4,420 4,388 4,781 5,095
Inventories, net
1,576 1,633 1,663 1,787 1,853 2,026 1,869 1,710 1,759 1,825 1,785
Prepaid Expenses
1,846 1,757 2,662 2,374 2,800 2,856 3,287 3,052 2,828 2,899 3,645
Plant, Property, & Equipment, net
5,479 5,540 5,572 5,317 5,321 5,346 5,391 5,414 5,421 5,459 5,500
Total Noncurrent Assets
42,941 42,511 40,822 40,723 36,930 35,916 34,354 34,408 34,112 35,545 35,160
Long-Term Investments
1,327 1,334 1,156 1,163 0.00 0.00 0.00 0.00 - 1,913 2,005
Goodwill
8,314 8,314 8,314 8,314 8,314 8,314 8,314 8,314 8,314 8,314 8,314
Intangible Assets
28,348 27,750 27,152 26,454 23,428 22,832 20,546 19,948 19,355 18,566 17,970
Noncurrent Deferred & Refundable Income Taxes
- - - - - - - - 2,572 2,721 1,998
Other Noncurrent Operating Assets
4,952 5,113 4,200 4,792 5,188 4,770 5,494 6,146 3,871 4,031 4,873
Total Liabilities & Shareholders' Equity
61,876 62,337 62,373 62,125 56,292 53,579 54,525 58,995 56,434 55,721 58,533
Total Liabilities
40,937 41,243 40,130 39,376 38,837 35,384 36,134 39,749 37,355 36,130 37,078
Total Current Liabilities
10,528 13,964 11,945 11,280 13,015 10,781 11,725 12,004 12,344 11,189 12,298
Short-Term Debt
2,283 4,037 1,793 1,798 3,667 1,810 1,812 1,815 2,806 2,806 2,806
Accounts Payable
627 622 586 550 622 537 903 833 737 582 808
Accrued Expenses
3,477 3,494 3,714 3,802 4,263 3,923 4,113 3,892 4,185 4,215 4,931
Other Current Liabilities
4,140 5,810 5,852 5,130 4,464 4,510 4,896 5,464 4,615 3,586 3,752
Total Noncurrent Liabilities
30,409 27,279 28,185 28,096 25,822 24,603 24,409 27,745 25,011 24,941 24,780
Long-Term Debt
22,956 21,209 23,189 23,189 21,527 21,540 21,437 24,896 22,146 22,140 22,135
Noncurrent Deferred Revenue
3,775 2,610 2,088 2,039 1,967 738 782 830 819 859 866
Noncurrent Deferred & Payable Income Tax Liabilities
2,401 2,106 1,984 1,588 933 907 794 724 709 652 597
Other Noncurrent Operating Liabilities
1,277 1,354 924 1,280 1,395 1,418 1,396 1,295 1,337 1,290 1,182
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
20,939 21,094 22,242 22,749 17,455 18,197 18,390 19,246 19,078 19,590 21,456
Total Preferred & Common Equity
20,997 21,158 22,314 22,833 17,539 18,281 18,475 19,330 19,162 19,674 21,540
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
20,997 21,157 22,313 22,833 17,539 18,281 18,474 19,330 19,162 19,675 21,540
Common Stock
5,794 6,009 6,280 6,501 6,814 7,023 7,328 7,701 8,139 8,368 8,679
Retained Earnings
15,223 15,138 16,002 16,304 10,656 11,165 11,073 11,497 10,931 11,325 12,825
Accumulated Other Comprehensive Income / (Loss)
-20 10 31 28 69 93 73 132 92 -18 36
Noncontrolling Interest
-58 -64 -72 -84 -84 -84 -84 -84 -84 -84 -84

Annual Metrics And Ratios for Gilead Sciences

This table displays calculated financial ratios and metrics derived from Gilead Sciences' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
31.13% -6.89% -14.09% -15.25% 1.46% 9.98% 10.60% -0.09% -0.60% 6.04% 2.40%
EBITDA Growth
43.68% -18.03% -17.10% -35.32% -26.65% -45.32% 174.11% -21.86% 18.57% -57.75% 206.20%
EBIT Growth
46.36% -19.18% -18.90% -39.40% -30.66% -56.90% 249.76% -27.27% 15.62% -78.62% 548.68%
NOPAT Growth
49.72% -25.02% -65.15% 18.41% -22.37% -95.13% 3,322.36% -22.52% 8.09% -81.46% 654.60%
Net Income Growth
50.15% -25.51% -65.57% 17.57% -1.76% -98.34% 6,867.42% -26.37% 22.93% -91.45% 1,672.92%
EPS Growth
62.04% -16.54% -64.69% 18.80% 1.20% -97.63% 4,830.00% -26.17% 23.63% -91.56% 1,684.21%
Operating Cash Flow Growth
65.78% -19.78% -30.20% -29.40% 8.86% -10.67% 39.37% -20.31% -11.75% 35.25% -7.47%
Free Cash Flow Firm Growth
71.04% -22.68% -94.67% 593.73% -93.08% -5,155.00% 145.85% -25.35% -16.80% -21.42% 71.79%
Invested Capital Growth
-9.39% -10.91% 30.16% -0.03% 23.40% 94.89% -4.27% -2.81% 1.29% -8.50% 2.73%
Revenue Q/Q Growth
3.79% -3.76% -4.99% -0.69% 0.38% 6.66% -0.64% 0.53% -1.00% 1.61% 1.22%
EBITDA Q/Q Growth
5.92% -7.10% -9.42% -10.34% 12.89% 0.34% -7.93% 16.49% -1.81% 13.20% -0.65%
EBIT Q/Q Growth
6.21% -7.58% -10.74% -11.47% 16.48% -2.32% -10.46% 22.96% -4.33% 44.29% -0.76%
NOPAT Q/Q Growth
7.52% -10.57% -59.59% 237.55% 63.99% -87.71% -19.08% 31.63% -6.46% 116.70% 1.17%
Net Income Q/Q Growth
7.24% -10.52% -59.89% 236.83% 100.30% -92.79% -15.85% 37.99% -3.71% 321.05% 4.93%
EPS Q/Q Growth
3.03% -7.71% -60.02% 239.02% 100.95% -89.80% -16.16% 37.36% -3.23% 322.22% 4.95%
Operating Cash Flow Q/Q Growth
15.01% -11.69% -6.20% -4.63% 2.64% -7.52% 12.77% -6.57% -4.74% 8.04% 3.64%
Free Cash Flow Firm Q/Q Growth
12.90% -12.65% -92.90% 224.28% -79.35% -1,614.20% 174.14% -6.50% -15.66% 43.51% -5.42%
Invested Capital Q/Q Growth
-0.64% 3.97% 31.87% -10.97% 5.57% 101.40% -5.65% -1.34% 0.27% -1.74% -0.25%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
87.73% 85.98% 83.26% 78.07% 79.18% 81.48% 75.82% 79.26% 76.04% 78.26% 78.83%
EBITDA Margin
71.83% 63.24% 61.03% 46.57% 33.67% 16.74% 41.49% 32.45% 38.71% 15.42% 46.12%
Operating Margin
68.00% 58.02% 54.10% 37.06% 19.10% 16.49% 36.32% 26.87% 28.05% 5.78% 34.04%
EBIT Margin
68.47% 59.43% 56.10% 40.11% 27.42% 10.75% 33.98% 24.74% 28.78% 5.80% 36.75%
Profit (Net Income) Margin
55.47% 44.38% 17.79% 24.68% 23.89% 0.36% 22.71% 16.74% 20.70% 1.67% 28.90%
Tax Burden Percent
83.60% 78.89% 34.33% 70.01% 103.95% 5.33% 74.91% 78.53% 81.83% 69.57% 86.87%
Interest Burden Percent
96.92% 94.66% 92.37% 87.87% 83.83% 62.91% 89.21% 86.15% 87.90% 41.37% 90.54%
Effective Tax Rate
16.40% 21.11% 65.67% 29.99% -3.95% 94.67% 25.09% 21.47% 18.18% 30.58% 13.13%
Return on Invested Capital (ROIC)
117.89% 98.34% 31.61% 33.09% 23.00% 0.69% 18.20% 14.62% 15.93% 3.07% 23.88%
ROIC Less NNEP Spread (ROIC-NNEP)
143.58% 106.64% 36.05% 40.74% -10.38% -0.46% 12.40% 8.09% 12.36% -0.98% 22.62%
Return on Net Nonoperating Assets (RNNOA)
-14.28% -28.23% -8.31% -7.12% 1.28% -0.25% 13.37% 6.98% 9.61% -0.78% 16.78%
Return on Equity (ROE)
103.61% 70.11% 23.30% 25.98% 24.28% 0.44% 31.57% 21.60% 25.54% 2.29% 40.66%
Cash Return on Invested Capital (CROIC)
127.74% 109.89% 5.40% 33.12% 2.05% -63.67% 22.57% 17.47% 14.65% 11.95% 21.18%
Operating Return on Assets (OROA)
51.74% 33.23% 23.02% 13.25% 9.82% 4.08% 13.61% 10.29% 12.46% 2.75% 18.34%
Return on Assets (ROA)
41.92% 24.82% 7.30% 8.15% 8.56% 0.14% 9.10% 6.96% 8.96% 0.79% 14.42%
Return on Common Equity (ROCE)
100.68% 68.18% 22.99% 25.85% 24.13% 0.43% 31.56% 21.62% 25.60% 2.30% 40.82%
Return on Equity Simple (ROE_SIMPLE)
97.69% 71.41% 22.72% 25.53% 23.81% 0.49% 29.43% 21.50% 24.58% 2.48% 0.00%
Net Operating Profit after Tax (NOPAT)
18,552 13,911 4,848 5,741 4,456 217 7,430 5,757 6,222 1,154 8,706
NOPAT Margin
56.84% 45.77% 18.57% 25.94% 19.85% 0.88% 27.21% 21.10% 22.95% 4.01% 29.57%
Net Nonoperating Expense Percent (NNEP)
-25.69% -8.30% -4.45% -7.65% 33.38% 1.15% 5.80% 6.53% 3.57% 4.05% 1.26%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - 12.40% 13.04% 2.51% 18.31%
Cost of Revenue to Revenue
12.27% 14.02% 16.74% 21.93% 20.83% 18.52% 24.18% 20.74% 23.96% 21.74% 21.17%
SG&A Expenses to Revenue
10.50% 11.18% 14.85% 18.33% 19.52% 20.86% 19.21% 20.79% 22.46% 21.18% 19.61%
R&D to Revenue
9.23% 16.78% 14.30% 22.68% 40.56% 44.13% 20.29% 21.70% 25.35% 36.76% 23.17%
Operating Expenses to Revenue
19.73% 27.96% 29.16% 41.01% 60.08% 64.99% 39.50% 52.40% 47.99% 72.48% 44.79%
Earnings before Interest and Taxes (EBIT)
22,347 18,061 14,647 8,876 6,155 2,653 9,279 6,749 7,803 1,668 10,820
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
23,445 19,219 15,933 10,305 7,559 4,133 11,329 8,852 10,496 4,435 13,580
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
5.79 3.76 3.55 3.02 3.03 3.46 3.89 4.69 4.25 5.96 6.71
Price to Tangible Book Value (P/TBV)
15.08 8.12 0.00 42.21 14.76 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
3.29 2.34 2.78 2.92 3.04 2.55 3.00 3.65 3.58 4.00 5.17
Price to Earnings (P/E)
5.92 5.26 15.66 11.85 12.67 512.71 13.17 21.69 17.12 239.83 17.89
Dividend Yield
1.73% 3.41% 3.75% 4.56% 4.67% 5.41% 4.34% 3.68% 3.85% 3.33% 2.57%
Earnings Yield
16.88% 19.01% 6.39% 8.44% 7.90% 0.20% 7.59% 4.61% 5.84% 0.42% 5.59%
Enterprise Value to Invested Capital (EV/IC)
6.93 4.91 4.00 3.49 3.13 2.08 2.53 3.02 2.89 3.66 4.51
Enterprise Value to Revenue (EV/Rev)
3.18 2.15 2.66 2.74 2.99 3.51 3.69 4.30 4.18 4.58 5.66
Enterprise Value to EBITDA (EV/EBITDA)
4.42 3.41 4.36 5.88 8.88 20.95 8.90 13.24 10.81 29.71 12.26
Enterprise Value to EBIT (EV/EBIT)
4.64 3.62 4.74 6.83 10.90 32.63 10.87 17.36 14.54 78.99 15.39
Enterprise Value to NOPAT (EV/NOPAT)
5.59 4.70 14.31 10.56 15.06 398.80 13.58 20.35 18.23 114.19 19.13
Enterprise Value to Operating Cash Flow (EV/OCF)
4.88 3.84 5.83 7.22 7.34 10.60 8.86 12.92 14.17 12.17 16.62
Enterprise Value to Free Cash Flow (EV/FCFF)
5.16 4.21 83.78 10.55 168.80 0.00 10.95 17.04 19.83 29.30 21.56
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
1.15 1.36 1.64 1.27 1.09 1.72 1.27 1.19 1.10 1.39 1.10
Long-Term Debt to Equity
1.10 1.36 1.50 1.14 0.98 1.57 1.20 1.08 1.02 1.29 0.98
Financial Leverage
-0.10 -0.26 -0.23 -0.17 -0.12 0.54 1.08 0.86 0.78 0.79 0.74
Leverage Ratio
2.47 2.82 3.19 3.19 2.84 3.18 3.47 3.10 2.85 2.88 2.82
Compound Leverage Factor
2.40 2.67 2.95 2.80 2.38 2.00 3.10 2.67 2.51 1.19 2.55
Debt to Total Capital
53.57% 57.64% 62.07% 55.92% 52.06% 63.28% 55.90% 54.33% 52.34% 58.12% 52.44%
Short-Term Debt to Total Capital
2.39% 0.00% 5.08% 5.62% 5.29% 5.56% 3.17% 4.89% 3.77% 3.95% 5.90%
Long-Term Debt to Total Capital
51.19% 57.64% 56.98% 50.30% 46.77% 57.73% 52.72% 49.43% 48.58% 54.17% 46.53%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
1.41% 1.04% 0.11% 0.30% 0.26% 0.04% -0.01% -0.07% -0.18% -0.18% -0.18%
Common Equity to Total Capital
45.02% 41.32% 37.83% 43.78% 47.68% 36.68% 44.12% 45.74% 47.83% 42.06% 47.74%
Debt to EBITDA
0.94 1.37 2.11 2.65 3.25 7.60 2.36 2.85 2.38 6.02 1.84
Net Debt to EBITDA
-0.18 -0.31 -0.20 -0.41 -0.17 5.68 1.67 1.99 1.58 3.77 1.06
Long-Term Debt to EBITDA
0.90 1.37 1.93 2.38 2.92 6.93 2.22 2.59 2.21 5.61 1.63
Debt to NOPAT
1.19 1.89 6.92 4.76 5.52 144.65 3.59 4.38 4.02 23.15 2.86
Net Debt to NOPAT
-0.22 -0.43 -0.65 -0.73 -0.28 108.21 2.54 3.06 2.66 14.49 1.65
Long-Term Debt to NOPAT
1.14 1.89 6.35 4.28 4.96 131.95 3.39 3.99 3.73 21.58 2.54
Altman Z-Score
4.86 3.38 2.66 2.62 2.58 1.62 2.29 2.62 2.79 2.74 4.07
Noncontrolling Interest Sharing Ratio
2.83% 2.75% 1.34% 0.49% 0.62% 0.35% 0.04% -0.09% -0.26% -0.40% -0.40%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
2.50 2.13 2.74 3.38 3.10 1.40 1.27 1.29 1.43 1.60 1.55
Quick Ratio
2.07 1.78 2.52 3.15 2.86 1.08 0.95 0.99 1.06 1.20 1.06
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
20,102 15,544 828 5,746 397 -20,093 9,213 6,878 5,722 4,497 7,723
Operating Cash Flow to CapEx
2,844.71% 2,279.01% 2,016.61% 909.09% 1,108.36% 1,256.62% 1,966.15% 1,246.15% 1,368.55% 2,070.36% 1,779.57%
Free Cash Flow to Firm to Interest Expense
29.22 16.12 0.74 5.33 0.40 -20.42 9.20 7.36 6.06 4.60 7.54
Operating Cash Flow to Interest Expense
30.89 17.68 10.64 7.80 9.19 8.30 11.37 9.70 8.48 11.08 9.78
Operating Cash Flow Less CapEx to Interest Expense
29.80 16.91 10.11 6.94 8.36 7.64 10.79 8.92 7.86 10.55 9.23
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.76 0.56 0.41 0.33 0.36 0.38 0.40 0.42 0.43 0.47 0.50
Accounts Receivable Turnover
6.22 5.86 6.24 6.17 6.50 5.83 5.82 5.89 5.75 6.33 6.31
Inventory Turnover
2.40 2.41 3.66 6.01 5.39 3.51 4.00 3.62 3.95 3.58 3.58
Fixed Asset Turnover
16.53 11.82 8.48 6.06 5.28 5.21 5.41 5.15 5.03 5.36 5.34
Accounts Payable Turnover
3.76 3.57 4.33 6.05 6.22 1.55 2.24 7.03 8.93 9.04 8.05
Days Sales Outstanding (DSO)
58.65 62.26 58.48 59.20 56.17 62.64 62.73 62.01 63.51 57.63 57.85
Days Inventory Outstanding (DIO)
152.20 151.71 99.70 60.73 67.77 103.98 91.26 100.82 92.51 102.10 101.99
Days Payable Outstanding (DPO)
97.17 102.11 84.34 60.32 58.67 235.23 162.70 51.94 40.86 40.38 45.32
Cash Conversion Cycle (CCC)
113.68 111.86 73.84 59.62 65.26 -68.61 -8.71 110.89 115.16 119.35 114.53
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
14,962 13,329 17,349 17,344 21,403 41,713 39,930 38,809 39,309 35,966 36,950
Invested Capital Turnover
2.07 2.15 1.70 1.28 1.16 0.78 0.67 0.69 0.69 0.76 0.81
Increase / (Decrease) in Invested Capital
-1,550 -1,633 4,020 -5.00 4,059 20,310 -1,783 -1,121 500 -3,343 983
Enterprise Value (EV)
103,699 65,444 69,388 60,616 67,097 86,575 100,871 117,171 113,455 131,754 166,527
Market Capitalization
107,271 71,002 72,481 64,659 68,219 63,064 82,010 99,602 96,979 115,118 152,281
Book Value per Share
$12.86 $14.34 $15.65 $16.53 $17.80 $14.52 $16.80 $16.93 $18.32 $15.51 $18.30
Tangible Book Value per Share
$4.94 $6.64 ($0.63) $1.18 $3.65 ($18.37) ($16.52) ($12.73) ($9.58) ($7.17) ($2.09)
Total Capital
41,170 45,709 54,043 48,856 47,243 49,623 47,759 46,439 47,736 45,957 47,554
Total Debt
22,055 26,346 33,542 27,322 24,593 31,402 26,695 25,230 24,987 26,711 24,936
Total Long-Term Debt
21,073 26,346 30,795 24,574 22,094 28,645 25,179 22,957 23,189 24,896 22,129
Net Debt
-4,153 -6,034 -3,152 -4,190 -1,247 23,492 18,866 17,600 16,560 16,720 14,330
Capital Expenditures (CapEx)
747 748 590 924 825 650 579 728 585 523 563
Debt-free, Cash-free Net Working Capital (DFCFNWC)
1,247 -1,525 -2,575 -2,110 -1,316 -52 -1,842 -906 -661 -1,007 1,704
Debt-free Net Working Capital (DFNWC)
15,854 10,370 22,935 27,979 23,036 7,356 4,678 5,479 6,603 8,984 9,336
Net Working Capital (NWC)
14,872 10,370 20,188 25,231 20,537 4,599 3,162 3,206 4,805 7,169 6,529
Net Nonoperating Expense (NNE)
446 423 204 281 -908 128 1,229 1,191 609 674 196
Net Nonoperating Obligations (NNO)
-4,153 -6,034 -3,152 -4,190 -1,247 23,492 18,866 17,600 16,560 16,720 14,332
Total Depreciation and Amortization (D&A)
1,098 1,158 1,286 1,429 1,404 1,480 2,050 2,103 2,693 2,767 2,760
Debt-free, Cash-free Net Working Capital to Revenue
3.82% -5.02% -9.86% -9.54% -5.86% -0.21% -6.75% -3.32% -2.44% -3.50% 5.79%
Debt-free Net Working Capital to Revenue
48.57% 34.12% 87.85% 126.45% 102.61% 29.79% 17.13% 20.08% 24.35% 31.24% 31.71%
Net Working Capital to Revenue
45.57% 34.12% 77.33% 114.03% 91.48% 18.63% 11.58% 11.75% 17.72% 24.93% 22.18%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$12.37 $10.08 $3.54 $4.20 $4.24 $0.10 $4.96 $3.66 $4.54 $0.38 $6.84
Adjusted Weighted Average Basic Shares Outstanding
1.46B 1.34B 1.31B 1.30B 1.27B 1.26B 1.26B 1.26B 1.25B 1.25B 1.24B
Adjusted Diluted Earnings per Share
$11.91 $9.94 $3.51 $4.17 $4.22 $0.10 $4.93 $3.64 $4.50 $0.38 $6.78
Adjusted Weighted Average Diluted Shares Outstanding
1.52B 1.36B 1.32B 1.31B 1.28B 1.26B 1.26B 1.26B 1.26B 1.26B 1.26B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
1.37B 1.31B 1.31B 1.28B 1.26B 1.26B 1.25B 1.25B 1.25B 1.25B 1.24B
Normalized Net Operating Profit after Tax (NOPAT)
18,552 13,911 9,887 5,741 3,001 2,850 7,430 7,877 6,263 4,056 9,219
Normalized NOPAT Margin
56.84% 45.77% 37.87% 25.94% 13.37% 11.54% 27.21% 28.87% 23.10% 14.10% 31.31%
Pre Tax Income Margin
66.36% 56.26% 51.82% 35.25% 22.99% 6.76% 30.32% 21.31% 25.30% 2.40% 33.27%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
32.48 18.74 13.10 8.24 6.19 2.70 9.27 7.22 8.27 1.71 10.57
NOPAT to Interest Expense
26.97 14.43 4.34 5.33 4.48 0.22 7.42 6.16 6.59 1.18 8.50
EBIT Less CapEx to Interest Expense
31.40 17.96 12.57 7.38 5.36 2.04 8.69 6.44 7.65 1.17 10.02
NOPAT Less CapEx to Interest Expense
25.88 13.65 3.81 4.47 3.65 -0.44 6.84 5.38 5.97 0.65 7.95
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
10.35% 18.20% 58.81% 54.41% 60.07% 3,875.28% 58.14% 81.23% 67.86% 816.25% 47.04%
Augmented Payout Ratio
65.59% 99.76% 79.35% 107.53% 92.67% 5,653.93% 66.94% 111.80% 85.68% 1,055.83% 69.62%

Quarterly Metrics And Ratios for Gilead Sciences

This table displays calculated financial ratios and metrics derived from Gilead Sciences' official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
5.42% 0.13% -3.72% 5.26% 5.38% 7.01% 6.40% -0.28% 1.84% 2.97% 4.70%
EBITDA Growth
10.04% 1.54% -6.93% -263.10% 19.42% -41.76% 19.95% 173.57% 13.07% 143.21% -2.86%
EBIT Growth
4.13% -4.13% -15.64% -376.36% 25.98% -53.19% 26.89% 145.12% 17.17% 226.30% -3.44%
NOPAT Growth
-28.90% 17.97% -24.19% -334.43% 90.93% -52.65% 45.92% 158.96% -3.97% 139.61% 3.37%
Net Income Growth
-8.46% 21.61% -13.23% -523.35% 55.34% -42.31% 25.83% 131.53% 21.44% 143.58% 22.43%
EPS Growth
-8.79% 21.83% -11.63% -517.50% 55.42% -42.20% 25.44% 131.14% 20.93% 143.00% 22.38%
Operating Cash Flow Growth
29.74% -38.70% -15.50% 27.24% -43.33% 145.53% 37.16% -20.82% -37.58% -4.66% 11.83%
Free Cash Flow Firm Growth
-52.86% -48.85% -70.04% -217.42% -24.51% 45.32% 507.74% 282.68% 104.10% -37.61% -79.45%
Invested Capital Growth
-2.77% -0.34% 1.29% -2.70% 1.13% -6.63% -8.50% -4.81% -3.51% 1.20% 2.73%
Revenue Q/Q Growth
3.89% 6.85% 0.89% -6.02% 4.01% 8.50% 0.32% -11.92% 6.22% 9.70% 2.01%
EBITDA Q/Q Growth
15.06% 29.50% -19.88% -236.61% 184.24% -36.84% 65.02% -16.21% 29.48% 35.84% -34.09%
EBIT Q/Q Growth
18.68% 40.40% -25.36% -322.22% 154.10% -47.84% 102.35% -20.99% 40.49% 45.26% -40.12%
NOPAT Q/Q Growth
-15.59% 125.61% -43.78% -318.94% 168.75% -44.04% 73.25% -11.53% 11.96% 39.63% -25.26%
Net Income Q/Q Growth
5.48% 109.05% -34.76% -394.28% 138.71% -22.37% 42.30% -26.25% 49.05% 55.71% -28.47%
EPS Q/Q Growth
3.75% 108.43% -34.10% -392.98% 138.62% -22.48% 43.00% -27.27% 50.00% 55.77% -27.98%
Operating Cash Flow Q/Q Growth
34.06% -24.94% 23.59% 2.31% -40.29% 225.21% -30.96% -40.94% -52.93% 396.74% -19.01%
Free Cash Flow Firm Q/Q Growth
29.66% 18.82% -65.96% -323.89% 183.36% 128.74% 42.35% -32.70% -6.86% -30.08% -53.11%
Invested Capital Q/Q Growth
-1.64% 2.26% 0.27% -3.51% 2.23% -5.60% -1.74% 0.39% 3.62% -0.98% -0.25%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
78.15% 77.80% 70.62% 76.79% 77.80% 79.14% 79.11% 76.90% 78.81% 79.80% 79.51%
EBITDA Margin
37.85% 45.88% 36.44% -52.96% 42.90% 24.97% 41.08% 39.07% 47.63% 58.98% 38.11%
Operating Margin
25.23% 37.20% 22.66% -64.64% 38.02% 11.77% 32.40% 33.55% 34.93% 42.82% 25.03%
EBIT Margin
27.53% 36.18% 26.76% -63.28% 32.92% 15.83% 31.92% 28.63% 37.87% 50.15% 29.44%
Profit (Net Income) Margin
15.74% 30.80% 19.92% -62.37% 23.21% 16.61% 23.56% 19.72% 27.68% 39.28% 27.55%
Tax Burden Percent
65.43% 93.70% 85.72% 92.96% 78.62% 131.07% 82.28% 79.75% 80.69% 83.82% 105.10%
Interest Burden Percent
87.40% 90.87% 86.82% 106.03% 89.69% 80.07% 89.69% 86.38% 90.57% 93.45% 89.03%
Effective Tax Rate
34.57% 6.30% 14.28% 0.00% 21.33% -31.07% 17.77% 20.25% 19.27% 16.18% -5.06%
Return on Invested Capital (ROIC)
11.62% 24.31% 13.49% -32.30% 21.57% 11.52% 20.35% 20.77% 21.37% 28.35% 21.24%
ROIC Less NNEP Spread (ROIC-NNEP)
11.35% 22.69% 13.69% -38.24% 19.11% 12.02% 18.95% 18.27% 21.17% 29.91% 21.88%
Return on Net Nonoperating Assets (RNNOA)
10.02% 18.47% 10.64% -38.36% 18.39% 10.41% 15.02% 18.75% 21.52% 25.37% 16.23%
Return on Equity (ROE)
21.64% 42.78% 24.12% -70.67% 39.96% 21.93% 35.37% 39.52% 42.89% 53.73% 37.47%
Cash Return on Invested Capital (CROIC)
18.94% 17.28% 14.65% 4.48% 3.33% 8.27% 11.95% 24.33% 22.10% 22.17% 21.18%
Operating Return on Assets (OROA)
12.04% 15.86% 11.58% -29.40% 15.79% 7.66% 15.16% 14.60% 20.00% 25.80% 14.69%
Return on Assets (ROA)
6.89% 13.51% 8.62% -28.98% 11.13% 8.04% 11.18% 10.06% 14.62% 20.21% 13.74%
Return on Common Equity (ROCE)
21.69% 42.88% 24.19% -70.93% 40.11% 22.01% 35.51% 39.71% 43.08% 53.96% 37.62%
Return on Equity Simple (ROE_SIMPLE)
25.73% 26.12% 0.00% 2.61% 5.65% 0.62% 0.00% 31.13% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
1,089 2,458 1,382 -3,025 2,080 1,164 2,016 1,784 1,997 2,789 2,084
NOPAT Margin
16.51% 34.86% 19.42% -45.25% 29.91% 15.43% 26.64% 26.76% 28.20% 35.90% 26.30%
Net Nonoperating Expense Percent (NNEP)
0.28% 1.62% -0.21% 5.94% 2.46% -0.51% 1.40% 2.50% 0.19% -1.56% -0.64%
Return On Investment Capital (ROIC_SIMPLE)
- - 2.89% - - - 4.39% 4.05% 4.48% 6.01% 4.38%
Cost of Revenue to Revenue
21.85% 22.20% 29.38% 23.21% 22.20% 20.86% 20.89% 23.10% 21.19% 20.20% 20.49%
SG&A Expenses to Revenue
28.02% 18.65% 22.59% 20.57% 19.80% 18.99% 25.18% 18.87% 19.27% 17.47% 22.64%
R&D to Revenue
24.90% 21.95% 24.66% 84.52% 19.97% 25.18% 21.54% 24.48% 21.91% 19.51% 26.79%
Operating Expenses to Revenue
52.92% 40.60% 47.95% 141.43% 39.78% 67.37% 46.72% 43.35% 43.87% 36.98% 54.47%
Earnings before Interest and Taxes (EBIT)
1,817 2,551 1,904 -4,231 2,289 1,194 2,416 1,909 2,682 3,896 2,333
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
2,498 3,235 2,592 -3,541 2,983 1,884 3,109 2,605 3,373 4,582 3,020
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
4.36 4.02 4.25 5.14 4.68 5.65 5.96 7.28 7.01 6.39 6.71
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
3.37 3.27 3.58 3.28 3.07 3.69 4.00 4.86 4.78 4.74 5.17
Price to Earnings (P/E)
16.82 15.26 17.12 185.91 81.10 821.89 239.83 23.39 21.85 16.98 17.89
Dividend Yield
4.00% 4.14% 3.85% 4.17% 4.43% 3.65% 3.33% 2.77% 2.81% 2.83% 2.57%
Earnings Yield
5.94% 6.55% 5.84% 0.54% 1.23% 0.12% 0.42% 4.27% 4.58% 5.89% 5.59%
Enterprise Value to Invested Capital (EV/IC)
2.85 2.72 2.89 2.91 2.73 3.35 3.66 4.33 4.16 4.14 4.51
Enterprise Value to Revenue (EV/Rev)
4.00 3.89 4.18 4.03 3.81 4.33 4.58 5.45 5.39 5.27 5.66
Enterprise Value to EBITDA (EV/EBITDA)
10.29 9.97 10.81 23.11 20.11 31.27 29.71 14.79 14.19 11.21 12.26
Enterprise Value to EBIT (EV/EBIT)
13.24 13.06 14.54 54.17 42.17 105.98 78.99 20.04 18.98 14.05 15.39
Enterprise Value to NOPAT (EV/NOPAT)
17.44 16.02 18.23 164.50 61.70 230.09 114.19 21.78 22.06 17.81 19.13
Enterprise Value to Operating Cash Flow (EV/OCF)
11.50 12.68 14.17 13.04 14.19 12.22 12.17 15.10 15.77 15.85 16.62
Enterprise Value to Free Cash Flow (EV/FCFF)
14.86 15.70 19.83 64.16 82.57 39.10 29.30 17.37 18.49 18.77 21.56
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
1.20 1.12 1.10 1.44 1.28 1.26 1.39 1.31 1.27 1.16 1.10
Long-Term Debt to Equity
1.01 1.04 1.02 1.23 1.18 1.17 1.29 1.16 1.13 1.03 0.98
Financial Leverage
0.88 0.81 0.78 1.00 0.96 0.87 0.79 1.03 1.02 0.85 0.74
Leverage Ratio
3.03 2.89 2.85 3.08 2.95 2.88 2.88 3.09 2.89 2.84 2.82
Compound Leverage Factor
2.65 2.62 2.47 3.26 2.65 2.30 2.59 2.67 2.62 2.65 2.51
Debt to Total Capital
54.48% 52.90% 52.34% 59.07% 56.20% 55.83% 58.12% 56.67% 56.01% 53.76% 52.44%
Short-Term Debt to Total Capital
8.71% 3.80% 3.77% 8.60% 4.36% 4.35% 3.95% 6.37% 6.30% 6.05% 5.90%
Long-Term Debt to Total Capital
45.77% 49.10% 48.58% 50.47% 51.84% 51.48% 54.17% 50.30% 49.71% 47.71% 46.53%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
-0.14% -0.15% -0.18% -0.20% -0.20% -0.20% -0.18% -0.19% -0.19% -0.18% -0.18%
Common Equity to Total Capital
45.66% 47.25% 47.83% 41.12% 44.00% 44.37% 42.06% 43.52% 44.18% 46.43% 47.74%
Debt to EBITDA
2.37 2.34 2.38 5.27 4.43 5.93 6.02 2.36 2.27 1.82 1.84
Net Debt to EBITDA
1.62 1.59 1.58 4.28 3.91 4.65 3.77 1.61 1.62 1.14 1.06
Long-Term Debt to EBITDA
1.99 2.17 2.21 4.50 4.09 5.47 5.61 2.09 2.02 1.62 1.63
Debt to NOPAT
4.02 3.76 4.02 37.49 13.60 43.67 23.15 3.47 3.54 2.90 2.86
Net Debt to NOPAT
2.75 2.55 2.66 30.47 11.98 34.21 14.49 2.37 2.53 1.81 1.65
Long-Term Debt to NOPAT
3.38 3.49 3.73 32.03 12.54 40.26 21.58 3.08 3.14 2.57 2.54
Altman Z-Score
2.22 2.35 2.48 1.92 2.44 2.68 2.78 3.23 3.33 3.37 3.60
Noncontrolling Interest Sharing Ratio
-0.20% -0.22% -0.26% -0.37% -0.37% -0.38% -0.40% -0.46% -0.45% -0.42% -0.40%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
1.02 1.34 1.43 1.08 1.14 1.26 1.60 1.37 1.32 1.45 1.55
Quick Ratio
0.78 0.98 1.06 0.72 0.69 0.82 1.20 1.00 0.89 1.01 1.06
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
2,180 2,591 882 -1,974 1,646 3,765 5,359 3,607 3,359 2,349 1,101
Operating Cash Flow to CapEx
1,682.01% 1,438.52% 1,008.84% 2,113.33% 1,019.23% 3,056.03% 2,023.81% 1,689.42% 772.90% 2,794.56% 1,622.93%
Free Cash Flow to Firm to Interest Expense
9.48 11.17 3.50 -7.77 6.94 15.82 21.61 13.87 13.23 9.18 4.34
Operating Cash Flow to Interest Expense
10.17 7.56 8.61 8.74 5.59 18.11 12.00 6.76 3.26 16.05 13.10
Operating Cash Flow Less CapEx to Interest Expense
9.56 7.04 7.75 8.32 5.04 17.51 11.40 6.36 2.83 15.47 12.29
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.44 0.44 0.43 0.46 0.48 0.48 0.47 0.51 0.53 0.51 0.50
Accounts Receivable Turnover
6.56 5.99 5.75 6.22 6.25 6.04 6.33 6.35 6.11 6.01 6.31
Inventory Turnover
3.60 3.71 3.95 3.88 3.69 3.83 3.58 3.45 3.22 3.39 3.58
Fixed Asset Turnover
5.05 5.02 5.03 5.08 5.11 5.16 5.36 5.35 5.34 5.34 5.34
Accounts Payable Turnover
9.49 9.67 8.93 10.65 11.65 9.08 9.04 9.18 11.07 7.24 8.05
Days Sales Outstanding (DSO)
55.63 60.92 63.51 58.71 58.36 60.47 57.63 57.52 59.71 60.75 57.85
Days Inventory Outstanding (DIO)
101.29 98.29 92.51 94.12 98.91 95.35 102.10 105.66 113.43 107.71 101.99
Days Payable Outstanding (DPO)
38.45 37.73 40.86 34.28 31.33 40.20 40.38 39.75 32.96 50.44 45.32
Cash Conversion Cycle (CCC)
118.47 121.49 115.16 118.55 125.95 115.63 119.35 123.43 140.18 118.02 114.53
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
38,340 39,205 39,309 37,929 38,774 36,604 35,966 36,106 37,412 37,044 36,950
Invested Capital Turnover
0.70 0.70 0.69 0.71 0.72 0.75 0.76 0.78 0.76 0.79 0.81
Increase / (Decrease) in Invested Capital
-1,091 -133 500 -1,051 434 -2,601 -3,343 -1,823 -1,362 440 983
Enterprise Value (EV)
109,435 106,538 113,455 110,559 105,972 122,508 131,754 156,483 155,650 153,233 166,527
Market Capitalization
92,254 89,648 96,979 90,167 85,478 104,380 115,118 139,541 137,914 137,730 152,281
Book Value per Share
$16.96 $17.91 $18.32 $14.07 $14.67 $14.84 $15.51 $15.39 $15.82 $17.36 $18.30
Tangible Book Value per Share
($11.95) ($10.56) ($9.58) ($11.39) ($10.33) ($8.34) ($7.17) ($6.83) ($5.79) ($3.82) ($2.09)
Total Capital
46,340 47,224 47,736 42,649 41,547 41,639 45,957 44,030 44,536 46,397 47,554
Total Debt
25,246 24,982 24,987 25,194 23,350 23,249 26,711 24,952 24,946 24,941 24,936
Total Long-Term Debt
21,209 23,189 23,189 21,527 21,540 21,437 24,896 22,146 22,140 22,135 22,129
Net Debt
17,245 16,962 16,560 20,476 20,578 18,212 16,720 17,026 17,820 15,587 14,330
Capital Expenditures (CapEx)
139 122 215 105 130 141 147 104 107 147 205
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-2,307 -1,036 -661 -25 574 -171 -1,007 -563 1,122 1,033 1,704
Debt-free Net Working Capital (DFNWC)
4,360 5,828 6,603 4,693 3,346 4,866 8,984 7,363 6,335 8,382 9,336
Net Working Capital (NWC)
323 4,035 4,805 1,026 1,536 3,054 7,169 4,557 3,529 5,576 6,529
Net Nonoperating Expense (NNE)
50 286 -35 1,145 466 -89 233 469 37 -263 -99
Net Nonoperating Obligations (NNO)
17,246 16,963 16,560 20,474 20,577 18,214 16,720 17,028 17,822 15,588 14,332
Total Depreciation and Amortization (D&A)
681 684 688 690 694 690 693 696 691 686 687
Debt-free, Cash-free Net Working Capital to Revenue
-8.43% -3.78% -2.44% -0.09% 2.06% -0.60% -3.50% -1.96% 3.89% 3.55% 5.79%
Debt-free Net Working Capital to Revenue
15.92% 21.28% 24.35% 17.10% 12.03% 17.20% 31.24% 25.62% 21.95% 28.82% 31.71%
Net Working Capital to Revenue
1.18% 14.73% 17.72% 3.74% 5.52% 10.79% 24.93% 15.86% 12.23% 19.17% 22.18%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.84 $1.75 $1.14 ($3.34) $1.29 $1.00 $1.43 $1.06 $1.57 $2.46 $1.75
Adjusted Weighted Average Basic Shares Outstanding
1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.25B 1.24B 1.24B
Adjusted Diluted Earnings per Share
$0.83 $1.73 $1.14 ($3.34) $1.29 $1.00 $1.43 $1.04 $1.56 $2.43 $1.75
Adjusted Weighted Average Diluted Shares Outstanding
1.26B 1.26B 1.26B 1.25B 1.25B 1.25B 1.26B 1.26B 1.26B 1.25B 1.26B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
1.25B 1.25B 1.25B 1.25B 1.24B 1.25B 1.25B 1.24B 1.24B 1.24B 1.24B
Normalized Net Operating Profit after Tax (NOPAT)
1,089 2,458 1,425 -1,324 2,080 1,847 2,016 1,784 2,151 2,789 1,669
Normalized NOPAT Margin
16.51% 34.86% 20.03% -19.81% 29.91% 24.47% 26.64% 26.76% 30.37% 35.90% 21.06%
Pre Tax Income Margin
24.06% 32.87% 23.24% -67.10% 29.52% 12.67% 28.63% 24.73% 34.30% 46.87% 26.21%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
7.90 11.00 7.56 -16.66 9.66 5.02 9.74 7.34 10.56 15.22 9.19
NOPAT to Interest Expense
4.74 10.59 5.48 -11.91 8.78 4.89 8.13 6.86 7.86 10.89 8.21
EBIT Less CapEx to Interest Expense
7.30 10.47 6.70 -17.07 9.11 4.42 9.15 6.94 10.14 14.64 8.38
NOPAT Less CapEx to Interest Expense
4.13 10.07 4.63 -12.32 8.23 4.30 7.54 6.46 7.44 10.32 7.40
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
69.02% 64.87% 67.86% 836.24% 373.48% 3,410.53% 816.25% 66.02% 62.75% 49.10% 47.04%
Augmented Payout Ratio
96.99% 93.03% 85.68% 1,054.59% 465.44% 4,243.86% 1,055.83% 90.83% 92.96% 74.28% 69.62%

Financials Breakdown Chart

Key Financial Trends

Here are the key takeaways from Gilead Sciences (GILD) quarterly results, focusing on trends in the last four years of data. Bullets are grouped by potential impact and ordered with positives first, then neutral, then negatives.

  • Q4 2025 quarterly revenue reached 7.93 billion USD, up from 6.67 billion USD in Q1 2025 and showing ongoing revenue growth through 2025.
  • Total Gross Profit in Q4 2025 was 6.30 billion USD on 7.93 billion USD of revenue, yielding a gross margin around 79%.
  • Operating cash flow remained strong, with net cash from continuing operating activities of 3.33 billion USD in Q4 2025.
  • Dividend per share remained attractive, with the 2025 period showing a meaningful ongoing return of capital (Q3 2025 dividend around 1.00 USD per share).
  • Balance sheet liquidity stayed solid: cash and equivalents around 7.3 billion USD and total current assets near 17.9 billion USD against total current liabilities around 12.3 billion USD (as of Q3 2025).
  • Debt load remained elevated but manageable: long-term debt about 22.1–22.3 billion USD, with interest expense around 254 million USD in Q4 2025, supported by strong cash flow.
  • R&D and SG&A expenses stayed high (R&D ~2.12 billion USD; SG&A ~1.79 billion USD in Q4 2025), reflecting ongoing pipeline and operations investment.
  • Total assets were about 58.5 billion USD and total equity around 21.5 billion USD as of mid-2025, indicating a solid capital base to support operations and investments.
  • Net income to common declined from Q3 2025’s peak (~3.05 billion USD) to Q4 2025 (~2.18 billion USD), signaling quarterly profitability volatility.
  • Investing and financing cash outflows were sizable in Q4 2025 (net investing around -1.84 billion USD and net financing around -1.26 billion USD), weighing on the cash balance despite strong operating cash flow.
05/07/26 08:21 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Gilead Sciences' Financials

When does Gilead Sciences' fiscal year end?

According to the most recent income statement we have on file, Gilead Sciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has Gilead Sciences' net income changed over the last 10 years?

Gilead Sciences' net income appears to be on a downward trend, with a most recent value of $8.51 billion in 2025, falling from $18.11 billion in 2015. The previous period was $480 million in 2024. View Gilead Sciences' forecast to see where analysts expect Gilead Sciences to go next.

What is Gilead Sciences' operating income?
Gilead Sciences' total operating income in 2025 was $10.02 billion, based on the following breakdown:
  • Total Gross Profit: $23.21 billion
  • Total Operating Expenses: $13.19 billion
How has Gilead Sciences' revenue changed over the last 10 years?

Over the last 10 years, Gilead Sciences' total revenue changed from $32.64 billion in 2015 to $29.44 billion in 2025, a change of -9.8%.

How much debt does Gilead Sciences have?

Gilead Sciences' total liabilities were at $36.41 billion at the end of 2025, a 8.4% decrease from 2024, and a 11.7% increase since 2015.

How much cash does Gilead Sciences have?

In the past 10 years, Gilead Sciences' cash and equivalents has ranged from $5.34 billion in 2021 to $17.94 billion in 2018, and is currently $7.56 billion as of their latest financial filing in 2025.

How has Gilead Sciences' book value per share changed over the last 10 years?

Over the last 10 years, Gilead Sciences' book value per share changed from 12.86 in 2015 to 18.30 in 2025, a change of 42.3%.



Financial statements for NASDAQ:GILD last updated on 2/27/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners